Dongha Kim

Prof. Dongha Kim

The Catholic University of Korea College of Medicine, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DKDongha Kim
Dongha Kim
HNHye Jin Nam
Hye Jin Nam
PARP inhibitors are the first clinically approved drugs that were developed based on synthetic lethality. PARP inhibitors have shown promising outcomes since their clinical applications and have recently been approved as maintenance treatment for cancer patients with BRCA mutations. PARP inhibitors also exhibit positive results even in patients without homologous recombination (HR) deficiency. Therapeutic effects were successfully achieved; however, the development of resistance was unavoidable. Approximately 40–70% of patients are likely to develop resistance. Here, we describe the mechanisms of action of PARP inhibitors, the causes of resistance, and the various efforts to overcome resistance. Particularly, we determined the survival probability of cancer patients according to the expression patterns of genes associated with HR restoration, which are critical for the development of PARP inhibitor resistance. Furthermore, we discuss the innovative attempts to degrade PARP proteins by chemically modifying PARP inhibitors. These efforts would enhance the efficacy of PARP inhibitors or expand the scope of their usage.

8 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
YYYoung Suk Yu
Young Suk Yu
HSHijai R. Shin
Hijai R. Shin
DKDongha Kim
Dongha Kim
SBSeon Ah Baek
Seon Ah Baek
SCSeon Ah Choi
Seon Ah Choi
SBSung Hee Baek
Sung Hee Baek
Autophagy is a catabolic process through which cytoplasmic components are degraded and recycled in response to various stresses including starvation. Recently, transcriptional and epigenetic regulations of autophagy have emerged as essential mechanisms for maintaining homeostasis. Here, we identify that coactivator-associated arginine methyltransferase 1 (CARM1) methylates Pontin chromatin-remodeling factor under glucose starvation, and methylated Pontin binds Forkhead Box O 3a (FOXO3a). Genome-wide analyses and biochemical studies reveal that methylated Pontin functions as a platform for recruiting Tip60 histone acetyltransferase with increased H4 acetylation and subsequent activation of autophagy genes regulated by FOXO3a. Surprisingly, CARM1-Pontin-FOXO3a signaling axis can work in the distal regions and activate autophagy genes through enhancer activation. Together, our findings provide a signaling axis of CARM1-Pontin-FOXO3a and further expand the role of CARM1 in nuclear regulation of autophagy.

17 November 2020 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
KHKyung Soo Hong
Kyung Soo Hong
JAJune Hong Ahn
June Hong Ahn
JJJong Geol Jang
Jong Geol Jang
JLJong Ho Lee
Jong Ho Lee
Hong Nam KimHong Nam Kim
Hong Nam Kim
WLWonhwa Lee
Wonhwa Lee
Anti-viral and anti-inflammatory drugs that suppress viral infection and severe inflammatory responses.

14 April 2025 in Molecular Oncology
Verified
Journal Article
Open access
DKDongha Kim
Dongha Kim
HNHye Jin Nam
Hye Jin Nam
SBSung Hee Baek
Sung Hee Baek
Transcription factors, pivotal in gene expression regulation, are essential in cancer progression. Their function is meticulously regulated by post‐translational modifications, including ubiquitination. This process, which marks proteins for degradation, can either enhance or inhibit the function of transcription factors, contingent on the context. In cancers, dysregulated ubiquitination of transcription factors contributes to the hallmark of uncontrolled growth and survival of tumors. For example, tumor suppressors such as p53 might be degraded prematurely due to abnormal ubiquitination, causing genomic instability. On the other hand, oncogenic transcription factors may gain stability via ubiquitination, thus facilitating tumorigenesis. Targeting the ubiquitin–proteasome system (UPS) therefore could be a viable therapeutic approach in cancer. Emerging treatments aim to block the ubiquitination of oncogenic transcription factors or to stabilize tumor suppressors. This review underscores the critical impact of transcription factor‐altered ubiquitination on cancer progression. Additionally, it outlines innovative therapeutic approaches that involve inhibitors or drugs directed at specific ubiquitin E3 ligases and deubiquitinases (DUBs) that regulate transcription factor activity.

1 January 2023 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
DKDongha Kim
Dongha Kim
Korean Circulation Journal 대한심장학회지 순환기 Kim D. Korean Circ J. 2023 May;53:e35. https://doi.org/10.4070/kcj.2023.0055